VR Adviser
Latest statistics and disclosures from VR Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Rayzebio, APGE, PHVS, VRDN, FDMT, and represent 50.55% of VR Adviser's stock portfolio.
- Added to shares of these 10 stocks: PHVS (+$51M), SYRE (+$51M), OCUL (+$35M), Ambrx Biopharma (+$30M), ARVN (+$26M), ATXS (+$25M), VRDN (+$17M), KALV (+$14M), CABA (+$13M), MRUS (+$12M).
- Started 8 new stock positions in ARVN, ABVX, ATXS, EYPT, Ambrx Biopharma, PRAX, SYRE, OCUL.
- Reduced shares in these 10 stocks: RYTM (-$27M), Ambrx Biopharma (-$24M), TVTX (-$24M), SVRA (-$17M), Praxis Precision Medicines I (-$9.1M), GHRS (-$8.3M), TSHA (-$7.1M), ACRS (-$7.1M), PLRX (-$5.0M), SGMT.
- Sold out of its positions in ACRS, Aeglea Biotherapeutics, Ambrx Biopharma, PLRX, Praxis Precision Medicines I, RLYB, SGMT, TVTX, Affimed Therapeutics B V.
- VR Adviser was a net buyer of stock by $187M.
- VR Adviser has $1.5B in assets under management (AUM), dropping by 53.49%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VR Adviser
VR Adviser holds 36 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Rayzebio | 17.2 | $251M | 4.0M | 62.17 |
|
|
| Apogee Therapeutics (APGE) | 16.3 | $237M | 8.5M | 27.94 |
|
|
| Pharvaris N V (PHVS) | 6.5 | $95M | +117% | 3.4M | 28.05 |
|
| Miragen Therapeutics (VRDN) | 5.8 | $85M | +25% | 3.9M | 21.78 |
|
| 4d Molecular Therapeutics In (FDMT) | 4.8 | $69M | +14% | 3.4M | 20.26 |
|
| Merus N V (MRUS) | 4.1 | $59M | +24% | 2.1M | 27.50 |
|
| Cabaletta Bio (CABA) | 4.0 | $58M | +29% | 2.6M | 22.70 |
|
| Spyre Therapeutics Com New (SYRE) | 3.5 | $51M | NEW | 2.4M | 21.52 |
|
| Kalvista Pharmaceuticals (KALV) | 3.4 | $50M | +40% | 4.1M | 12.25 |
|
| Enliven Therapeutics (ELVN) | 2.8 | $41M | 3.0M | 13.84 |
|
|
| Ocular Therapeutix (OCUL) | 2.4 | $35M | NEW | 7.8M | 4.46 |
|
| Hillevax (HLVX) | 2.3 | $33M | 2.1M | 16.05 |
|
|
| Ambrx Biopharma | 2.0 | $30M | NEW | 2.1M | 14.24 |
|
| Terns Pharmaceuticals (TERN) | 2.0 | $29M | +45% | 4.5M | 6.49 |
|
| Dyne Therapeutics (DYN) | 2.0 | $29M | 2.2M | 13.30 |
|
|
| Cogent Biosciences (COGT) | 1.9 | $28M | 4.7M | 5.88 |
|
|
| Celcuity (CELC) | 1.9 | $28M | -10% | 1.9M | 14.57 |
|
| Mersana Therapeutics (MRSN) | 1.8 | $26M | 11M | 2.32 |
|
|
| Arvinas Ord (ARVN) | 1.8 | $26M | NEW | 628k | 41.16 |
|
| Astria Therapeutics (ATXS) | 1.7 | $25M | NEW | 3.2M | 7.68 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.6 | $23M | -54% | 496k | 45.97 |
|
| Oric Pharmaceuticals (ORIC) | 1.5 | $22M | +13% | 2.4M | 9.20 |
|
| Applied Therapeutics (APLT) | 1.4 | $21M | +10% | 6.3M | 3.35 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.3 | $18M | -27% | 10M | 1.77 |
|
| Savara (SVRA) | 1.1 | $17M | -51% | 3.5M | 4.70 |
|
| Lyra Therapeutics (LYRA) | 0.9 | $14M | +178% | 2.6M | 5.24 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.7 | $11M | NEW | 999k | 10.70 |
|
| Dianthus Therapeutics (DNTH) | 0.7 | $9.6M | 928k | 10.40 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 0.5 | $7.9M | NEW | 354k | 22.28 |
|
| Gh Research Ordinary Shares (GHRS) | 0.5 | $7.6M | -51% | 1.3M | 5.80 |
|
| Acelyrin (SLRN) | 0.5 | $7.0M | +8% | 937k | 7.46 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.4 | $5.8M | NEW | 250k | 23.11 |
|
| Trevi Therapeutics (TRVI) | 0.3 | $4.6M | 3.4M | 1.34 |
|
|
| Adverum Biotechnologies | 0.3 | $3.9M | -21% | 5.1M | 0.75 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $1.5M | -58% | 925k | 1.67 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $1.1M | 77k | 14.03 |
|
Past Filings by VR Adviser
SEC 13F filings are viewable for VR Adviser going back to 2020
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023
- VR Adviser 2023 Q1 filed May 15, 2023
- VR Adviser 2022 Q4 filed Feb. 14, 2023
- VR Adviser 2022 Q3 filed Nov. 14, 2022
- VR Adviser 2022 Q2 filed Aug. 15, 2022
- VR Adviser 2022 Q1 filed May 16, 2022
- VR Adviser 2021 Q4 filed Feb. 14, 2022
- VR Adviser 2021 Q3 filed Nov. 15, 2021
- VR Adviser 2021 Q2 filed Aug. 13, 2021
- VR Adviser 2021 Q1 filed May 14, 2021
- VR Adviser 2020 Q4 filed Feb. 12, 2021